In case of emergency,
please contact the doctor listed below:

Doctor's Name/
Clinic, Center or
Hospital Name:

Doctor's
phone

(daratumumab)
DARZALEX®

PATIENT ALERT CARD

DARZALEX®

(daratumumab)

Information on risk prevention agreed with the Spanish Agency for Medicines and Health Products (AEMPS). February 2022

Available on the AEMPS website www.aemps.gob.es

INFORMATION FOR THE HEALTHCARE PROFESSIONAL

Daratumumab is associated with the risk of interference with blood typing. The Indirect Coombs test (Indirect antiglobulin test [IAT]) may show positive results in patients taking daratumumab, even in the absence of antibodies to minor blood antigens in the patient's serum which may persist for up to 6 months after the last dose. The determination of a patient's ABO and Rh blood type are not impacted.

If an emergency transfusion is required, non-cross-matched, ABO/RhD-compatible RBCs can be given per local blood bank practices.

For additional information, consult the summary of product characteristics of the drug available at the AEMPS Online Drug Information Center (CIMA) through the following link: https://cima.aemps.es/.

For more information, please contact local medical information service at Janssen: **contacto@its.jnj.com**

Daratumumab PATIENTS:
Provide this card to healthcare providers BEFORE blood transfusion and carry it for 6 months after treatment has ended.

For further information please refer to the Patient Information Leaflet. If you don't have it, ask your doctor or nurse for it

Name: _____

I am taking the following medication:
Daratumumab, a monoclonal antibody.

The date of the last injection was the day: ____ /____ /____
DD MM YYYY

Before starting daratumumab my blood test results collected on ____ /____ /____ were:
DD MM YYYY

Blood type: ☐ A ☐ B ☐ AB ☐ O ☐ Rh+ ☐ Rh-

Indirect Coombs test (antibody screening) was:

☐ Negative
☐ Positive for the following antibodies:

_____

Other: _____

Contact details of institution where the blood tests were performed:

_____

_____

Notification of adverse events: If you experience any type of adverse event, contact your doctor or pharmacist, even if you are dealing with possible adverse events that do not appear in the package leaflet. You can also notify them directly through the Spanish Pharmacovigilance System of medicines for human use: **https://www.notificaRAM.es**

Date of preparation: February 2022 · EM-88275. Versión RMP: 9.1 · Janssen-Cilag, S.A.